Shoe-stiffening inserts for first metatarsophalangeal joint osteoarthritis (the SIMPLE trial): study protocol for a randomised controlled trial by Munteanu, SE et al.
STUDY PROTOCOL Open Access
Shoe-stiffening inserts for first
metatarsophalangeal joint osteoarthritis
(the SIMPLE trial): study protocol for a
randomised controlled trial
Shannon E. Munteanu1,2*, Karl B. Landorf1,2,3, Jodie A. McClelland1,2, Edward Roddy4, Flavia M. Cicuttini5,
Alan Shiell1, Maria Auhl1,2, Jamie J. Allan1,2, Andrew K. Buldt1,2 and Hylton B. Menz1,2
Abstract
Background: This article describes the design of a parallel-group, participant- and assessor-blinded randomised
controlled trial comparing the effectiveness of shoe-stiffening inserts versus sham shoe insert(s) for reducing pain
associated with first metatarsophalangeal joint (MTPJ) osteoarthritis (OA).
Methods: Ninety participants with first MTPJ OA will be randomised to receive full-length shoe-stiffening insert(s)
(Carbon Fibre Spring Plate, Paris Orthotics, Vancouver, BC, Canada) plus rehabilitation therapy or sham shoe insert(s)
plus rehabilitation therapy. Outcome measures will be obtained at baseline, 4, 12, 24 and 52 weeks; the primary
endpoint for assessing effectiveness being 12 weeks. The primary outcome measure will be the foot pain domain
of the Foot Health Status Questionnaire (FHSQ). Secondary outcome measures will include the function domain
of the FHSQ, severity of first MTPJ pain (using a 100-mm Visual Analogue Scale), global change in symptoms
(using a 15-point Likert scale), health status (using the Short-Form-12® Version 2.0 and EuroQol (EQ-5D-5L™)
questionnaires), use of rescue medication and co-interventions, self-reported adverse events and physical activity levels
(using the Incidental and Planned Activity Questionnaire). Data will be analysed using the intention-to-treat principle.
Economic analysis (cost-effectiveness and cost-utility) will also be performed. In addition, the kinematic effects of the
interventions will be examined at 1 week using a three-dimensional motion analysis system and multisegment foot model.
Discussion: This study will determine whether shoe-stiffening inserts are a cost-effective intervention for relieving pain
associated with first MTPJ OA. The biomechanical analysis will provide useful insights into the mechanism of action of the
shoe-stiffening inserts.
Trial registration: Australian New Zealand Clinical Trials Registry, identifier: ACTRN12616000552482. Registered on 28 April
2016.
Keywords: Osteoarthritis, Metatarsophalangeal joint, Hallux rigidus, Foot orthoses
* Correspondence: s.munteanu@latrobe.edu.au
1Discipline of Podiatry, School of Allied Health, College of Science, Health
and Engineering, La Trobe University, Melbourne, VIC 3086, Australia
2La Trobe Sport and Exercise Medicine Research Centre, College of Science,
Health and Engineering, La Trobe University, Melbourne, VIC 3086, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Munteanu et al. Trials  (2017) 18:198 
DOI 10.1186/s13063-017-1936-1
Background
First metatarsophalangeal joint (MTPJ) osteoarthritis
(OA) (International Classification of Diseases (ICD-10)
code M20.20) is a common degenerative disorder of the
foot estimated to occur in 7.8% in people aged 50 years
or older, with a higher prevalence observed in women,
older people, and those from lower socioeconomic back-
grounds [1]. First MTPJ OA is characterised by localised
pain and stiffness [2]. This condition is associated with a
significant reduction in both foot-specific and general
health-related quality of life [3], with 71% of people with
first MTPJ OA reporting it to be disabling [1]. Increasing
radiographic severity of first MTPJ OA is associated with
an increased prevalence of pain, deformity and decreased
joint range of motion, suggesting that it may be a progres-
sive disorder which has an accumulative impact on
surrounding structures and the load-bearing function of
the foot [4].
There are structural changes (joint-space narrowing
and the formation of osteophytes at the dorsal aspect)
that characterise first MTPJ OA and lead to a restriction
in dorsiflexion motion at the joint. This restriction in
motion has been speculated to be a key factor in the
development of symptoms of first MTPJ OA by causing
dorsal compression of the joint during the propulsive
phase of gait when the first MTPJ is required to dorsiflex
[5]. In addition, the restricted joint dorsiflexion that
occurs in first MTPJ OA is associated with overloading
of the hallux and lesser forefoot during propulsion [6, 7],
as well as a shortened step length and longer stance
phase duration [8]. These changes may lead to the devel-
opment of secondary musculoskeletal complaints.
The treatment goals for first MTPJ OA are to re-
duce pain and stiffness, as well as to prevent further
degeneration of the joint [9, 10]. However, there are
no evidence-based guidelines for the management of
this condition. Nonetheless, nonsurgical management
is recognised as the first-line therapy for this condi-
tion [11], with numerous interventions recommended,
including pharmaceutical interventions, rehabilitation
therapy, taping, footwear modifications and orthotic
devices (such as foot orthoses or insoles) [12].
Despite the broad range of treatment options for this
disorder, very few have undergone rigorous scientific
evaluation [12]. Consequently, the choice of intervention
for this condition is frequently a matter of trial and
error, leading to increased costs and prolonged disability.
The existing evidence suggests that a 4-week supervised
rehabilitation therapy programme involving first MTPJ
mobilisation, toe-flexor strengthening, and gait retrain-
ing alleviates symptoms of first MTPJ OA (magnitude of
pain measured using a 0 to 10 pain scale reduced from
6.8 ± 1.5 to 0.4 ± 0.5) [13]. We have also found that pre-
fabricated arch-contouring foot orthoses with a cut-out
beneath the first MTPJ are equally effective as rocker-
sole footwear (footwear that has a rounded sole) for
reducing foot pain in people with this condition [14].
However, despite the positive symptom-modifying
effects of these interventions, approximately 50% of par-
ticipants either had no change or worsened [14], indicat-
ing that there is a need to further study other potential
interventions for this condition.
Shoe-stiffening inserts are also commonly recom-
mended as an intervention for first MTPJ OA [12]. Shoe-
stiffening inserts are made from a thin, semi-rigid material
that is placed inside the shoe with the objective of redu-
cing the rate and magnitude of dorsiflexion at the MTPJ
during the propulsive phase of gait [15, 16]. This action is
speculated to reduce the symptoms of first MTPJ OA by
decreasing the amount of motion and the resultant dorsal
compression at the first MTPJ that occurs during propul-
sion [15, 16]. Indeed, there is evidence to suggest that
shoe-stiffening inserts can reduce dorsiflexion of the first
MTPJ during gait [17]. Importantly, there is also evidence
to suggest that shoe-stiffening inserts may be effective at
reducing the symptoms of first MTPJ OA. Our recent
case-series feasibility study of 31 participants with first
MTPJ OA found clinically worthwhile improvements in
foot pain and foot-related disability at 3 months [18]. Fur-
ther, 78% of participants reported that the shoe-stiffening
inserts were effective. Whilst these findings are promising,
there is now a need to conduct a rigorous randomised
controlled trial and economic analysis to evaluate whether
this simple, noninvasive and relatively low-cost interven-
tion is effective. There is also a need to determine the ef-
fects of this intervention on foot function in this cohort to
understand the potential mechanism(s) of action. There-
fore, the primary aim of this project is to determine
whether shoe-stiffening inserts are more effective at redu-
cing pain of the first MTPJ in people with first MTPJ OA
compared to sham shoe inserts. The secondary aims are
to determine (1) whether shoe-stiffening inserts are more
effective at reducing first MTPJ dorsiflexion range of mo-
tion when walking compared to sham shoe inserts and (2)
whether shoe-stiffening inserts are a more cost-effective
treatment for first MTPJ OA compared to sham shoe
inserts.
Methods
This study protocol has been reported using the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines [19], and the associated
checklist is included as Additional file 1.
Design
This study is a parallel-group, participant- and assessor-
blinded, randomised controlled trial with a 52-week
follow-up (Fig. 1). Participants will be randomised to an
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experimental group (shoe-stiffening insert(s) (Carbon
Fibre Spring Plate, Paris Orthotics, Vancouver, BC,
Canada) or a control group (sham shoe insert(s)). To
ensure that all participants, who will have some level of
pain and disability, receive some form of intervention,
both groups will also be prescribed the same rehabilita-
tion therapy programme. This design covers any ethical
concerns of not treating participants in pain, but will
allow the effectiveness of the shoe-stiffening inserts to
be evaluated.
Due to the nature of the intervention, research staff
administering the shoe insert(s) cannot be blinded to
group allocation. However, research staff prescribing the
rehabilitation therapy (see later), assessing outcomes and
entering and analysing data will be blinded. Further,
participants will be blinded to their group allocation by
being informed that they will receive one of two differ-
ent shoe insert treatments and a rehabilitation therapy
programme for their condition.
Assessments will be performed at the La Trobe
University Health Sciences Clinic, Bundoora (VIC,
Australia) and the La Trobe University Gait Labora-
tory, Bundoora (VIC, Australia).
The study has been developed using the principles
described by Osteoarthritis Research Society Inter-
national (OARSI) Clinical Trials Task Force guidelines
[20] and recommendations for the conduct of efficacy
trials of treatment devices for OA by the Arthritis
Fig. 1 Trial profile
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Research UK Osteoarthritis and Crystal Diseases Clinical
Studies Group [21]. Publications associated with the trial
will be reported according to the Consolidated Standards of
Reporting Trials (CONSORT) 2010 Statement [22, 23]. The
study has been registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12616000552482).
Ethics approval
Ethics approval has been granted from the La Trobe
University Human Ethics Committee (number
HEC15-128). Informed consent will be obtained from
all participants. Ethical standards will adhere to the
National Health and Medical Research Council
(NHMRC) National Statement [24] and the World
Medical Association’s Declaration of Helsinki [25].
Participant recruitment and eligibility criteria
Participants will be recruited by advertisements placed
in local newspapers, by posters placed in senior citizens’
centres and retirement villages, mail-out advertisements
to health care practitioners in Melbourne, mail-out to
people currently accessing podiatry services at the La
Trobe University Health Sciences Clinic, and through
social networking media (e.g. Facebook, Twitter).
Inclusion criteria
To be included in this study, participants must: (1) be
aged at least 18 years, (2) report having pain in the first
MTPJ on most days for at least 12 weeks, (3) report hav-
ing pain rated at least 30 mm on a 100-mm Visual
Analogue Scale (VAS), (4) have pain upon palpation of
the dorsal aspect of the first MTPJ and restricted first
MTPJ dorsiflexion (less than 64° of dorsiflexion range of
motion) [26], (5) be able to walk household distances
(more than 50 m) without the aid of a walker, crutches
or cane, (6) be willing to have their foot X-rayed, (7)
agree to attempt to not receive additional interventions
(such as shoe modifications, physiotherapy, foot orth-
oses, intra-articular injections, or surgery) for the first
MTPJ pain during the course of the study, (8) be able to
reach their feet to perform ‘rehabilitation therapy’ of the
first MTPJ and (9) be willing to attempt to discontinue
consuming any pain relieving medications for first MTPJ
OA (except paracetamol (up to 4 g per day) which will
be rescue medication) for at least 14 days prior to the
baseline assessment and during the study period. Partici-
pants who consume paracetamol for first MTPJ pain
prior to recruitment will be advised to discontinue its
use at least 24 h prior to the baseline assessment and
follow-up assessments at 4, 12, 24 and 52 weeks.
Exclusion criteria
Exclusion criteria for participants in this study will be:
(1) previous first MTPJ surgery, (2) currently pregnant,
(3) significant first MTPJ deformity including hallux
valgus (defined as a score of 2 or 3 using the Man-
chester scale [27, 28]), (4) the presence of one or
more conditions within the foot or ankle that could
confound pain and functional assessments of the first
MTPJ such as forefoot pain that is not first MTPJ
OA, (5) the presence of any systemic inflammatory
condition such as gout or rheumatoid arthritis, (6)
any medical condition that, in the opinion of the
investigators, makes the participant unsuitable for
inclusion (e.g. clinically important pain in the muscu-
loskeletal system other than the first MTPJ), (7) an
inability to speak and read English, (8) cognitive
impairment, (9) intra-articular injections (such as
corticosteroids) to the first MTPJ in the previous
3 months, (10) unwilling to discontinue use of any
foot orthotic devices if currently wearing them, (11)
currently wearing shoe-stiffening inserts and (12)
regularly wear shoes that are not able to accommo-
date the shoe-stiffening inserts.
Baseline assessment
Participant characteristics, major medical conditions, health
status and anthropometrics
Participant characteristics (such as age, sex, weight,
height, education and income level), major medical
conditions and number of medications will be obtained
via a structured questionnaire. Health status will be
measured using the Short-Form-12 (SF-12®) Version 2.0
and the EuroQol 5D-5L™ (EQ-5D-5L™) questionnaires.
Height and weight will be measured using a stadiometer
and digital scales and Body Mass Index will be calcu-
lated as weight (kg)/height (m2). Static foot posture will
be assessed using the Foot Posture Index [29]. First
MTPJ dorsiflexion range of motion will be measured
using a reliable goniometric technique [26]. Footwear
will also be assessed using selected items from the Foot-
wear Assessment Tool [30].
Radiographic assessment
Participants will be required to undergo radiographic
imaging of their symptomatic foot (or most symptom-
atic foot) to grade the presence and severity of first
MTPJ OA. Dorso-plantar and lateral radiographic
projections will be obtained with the participant
weight-bearing in a relaxed bipedal stance position, as
described previously [31]. The severity of the osteo-
phytes and the joint-space narrowing at the first
MTPJ will be determined using the La Trobe Univer-
sity radiographic atlas for first MTPJ OA [31]. All
measures will be conducted by two experienced raters
(SEM, HBM) who were involved in the development
of the atlas. The atlas has excellent reliability [31].
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Interventions
Random allocation and concealment
Participants will be allocated to the intervention or
control groups using minimisation [32] incorporating
stratifications by age (18 to 40, 41 to 60, older than
61 years) and sex, using an interactive voice response
telephone service provided by the NHMRC Clinical Tri-
als Centre at the University of Sydney, Sydney, Australia.
Full-length shoe-stiffening inserts (intervention group)
Participants will be provided with full-length shoe-
stiffening inserts at the baseline assessment (a single
insert if symptoms are unilateral, or a pair of inserts if
symptoms are bilateral). The shoe-stiffening inserts are
light (32 to 48 g across the extra small to large size
range) and thin (1.5 mm) to allow easy fitting into differ-
ent types of footwear. The shoe-stiffening inserts are
commercially available and are fabricated from prepreg-
nated carbon (Carbon Fibre Spring Plate, Paris Orthotics
Ltd., Vancouver, BC, Canada) with the following design
characteristics: (1) full length that extends from the heel
to the tip of the toes, (2) no arch build-up or contour at
the heel and (3) contoured design from proximal to
distal to allow for the pitch of the shoe. To maximise
comfort and adherence, the inserts will be covered with
3.2-mm PPT® with an Ultralux top layer (PPT2 809 Blue,
Langer Biomechanics, Ronkonkoma, NY, USA). A
full-length piece of Cambrelle® (Camtex Fabrics Ltd.,
United Kingdom) will also be applied to the under-
side of the insert to make it look as similar as pos-
sible to the sham insert and to prevent abrasion
prematurely wearing the undersurface of the PPT®
(Fig. 2). The inserts will be dispensed by the study
investigators (JJA or AKB), both registered podiatrists
with a minimum 3 years of clinical experience.
Sham inserts (control group)
Participants allocated to the control group will receive
sham inserts (a single insert if symptoms are unilateral, or
a pair of inserts if symptoms are bilateral) that will be
designed to not affect first MTPJ dorsiflexion but appear
as identical to the shoe-stiffening inserts as possible. To
achieve this, the shoe-stiffening inserts (i.e. the same as
those provided to the intervention group) will be modified
by removing the distal end of the insert so that the anter-
ior edge finishes proximal to the level of the MTPJs at the
anterior margin of the heel. Similar to the inserts provided
to the intervention group, the sham inserts will be sand-
wiched between a full-length layer of 3.2-mm PPT® with
an Ultralux top layer (PPT2 809 Blue, Langer Biomechan-
ics, Ronkonkoma, NY, USA). A full-length piece of Cam-
brelle® (Camtex Fabrics Ltd., Cumbria, United Kingdom)
will also be applied to the underside of the insert (Fig. 2).
This sham insert device is necessary in this trial due to
participants’ expectation of receiving a ‘take-home’ inter-
vention (i.e. minimises resentful demoralisation). The
inserts will be dispensed by JJA or AKB.
Mechanical testing of the inserts has been con-
ducted to determine their effect on the bending stiff-
ness of the shoe. A standard Oxford shoe was affixed
to a shoe last that was cut at the level of the MTPJs
to provide a sagittal-plane axis. The shoe was then
dorsiflexed at 5° increments (commencing at 20° of
dorsiflexion), and the corresponding force was
recorded using a strain gauge. The average moment
obtained from an average of five repeated trials was
then calculated, as illustrated in Fig. 3. The bending
stiffness at 45° of dorsiflexion (the maximum dorsi-
flexion available with the shoe-stiffening insert placed
in the shoe) for each of the conditions was as follows:
shoe-only (0.027 Nm/deg), sham insert (0.029 Nm/deg)
Fig. 2 Shoe insert conditions. Panels a to c Shoe-stiffening inserts from side, top and bottom view; Panels d to f sham inserts from side,
top and bottom view
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and shoe-stiffening insert (0.208 Nm/deg). These results
confirm that the sham insert has a negligible effect on
bending stiffness, whereas the shoe-stiffening insert results
in an almost 10-fold increase in bending stiffness.
Rehabilitation therapy
Both groups will receive a standardised programme of
rehabilitation therapy that is based on a physiotherapy
programme for first MTPJ OA reported to be effect-
ive in a randomised trial [13]. This will be a home-
based programme performed daily for approximately
30 min for 12 weeks, then three times per week for
the remaining 40 weeks of the trial. Each therapy
session will involve: (1) application of a heat pack for
10 min, followed by (2) self-mobilisation of the first
MTPJ for 2 min (distraction and gliding), (3) toe-
flexor strengthening exercises (one set of 10 isometric
contractions each held for 10 s) and concluding with
(4) application of a cold pack (10 min). If the condi-
tion is bilateral, both feet will be treated. The
programme can be viewed at: https://www.youtube.-
com/watch?v=cHeO2H6s3K0&feature=youtu.be.
During the baseline assessment, participants will be
instructed to perform the exercises by JJA or AKB.
Instruction will be given prior to the shoe insert(s) being
allocated and dispensed so that JJA and AKB are blinded
to intervention allocation. Participants will be provided
with all necessary equipment, along with an instruction
booklet, so that the exercise programme can be
performed unsupervised at home. The rehabilitation
therapy will be reviewed at 1 and 12 weeks by research
personnel (SEM, KBL or HBM), registered podiatrists
with at least 19 years’ clinical experience each, blind to
intervention allocation. After the 12-week review, partic-
ipants will be telephoned at monthly intervals to remind
them to perform the therapy (to maximise adherence).
Rehabilitation therapy has been included as a co-
treatment, as using a sham treatment alone may be
considered withholding ‘usual’ care.
Treatment credibility/expectation
A participant’s expectations and their initial beliefs about
the credibility of a given intervention may affect the final
intervention outcome [33]. Treatment credibility (partici-
pants’ beliefs about the logic underpinning the interven-
tion) and treatment expectancy (participants’ perceptions
of how much they may benefit) will, therefore, be quanti-
fied using the Credibility/Expectancy Questionnaire
(CEQ) [34]. The CEQ will be administered after random-
isation and allocation. The CEQ consists of six items;
three are related to credibility and three are related to
expectancy. For each item, participants will be asked to
rate the credibility of the intervention and their expecta-
tions on a 9-point Likert scale. High scores on the scale
indicate that the participant considers the intervention to
be credible and expects it to be effective. The CEQ has
been shown to have good internal consistency and test-
retest reliability [34], and has recently been used to assess
the credibility of sham dry needling [35], sham foot
orthoses [36], as well as prefabricated foot orthoses and
rocker-sole footwear [14] in clinical trials evaluating
interventions for foot disorders.
Outcome measures
Primary and secondary outcome measures will be
collected at baseline and at 4, 12, 24 and 52 weeks.
These time points have been selected as 4 weeks is
considered the earliest time to detect an effect, 12 weeks
is considered to be a clinically feasible time point when
maximum effect would be expected and is, therefore,
the primary endpoint [21, 37], and 24 and 52 weeks will
allow us to determine the longer-term effects of the
interventions [38]. To minimise participant burden, pos-



























moment = F X d
stiffness = moment / a (in Nm/deg)
last
insert
Fig. 3 Mechanical testing of the inserts. The measurement of the
bending stiffness of the inserts placed inside an Oxford shoe
(upper panel) and the results of the stiffness of the shoe with and
without a sham and full-length shoe-stiffening insert (lower panel).
The stiffness of each condition is reflected in the gradient of the plots
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52 assessments. To minimise loss of follow-up data, par-
ticipants who do not return questionnaires will be
reminded up to three times to return their questionnaires.
Biomechanical analyses will be performed at 1 week:
this will minimise participant burden during the baseline
assessment and enable some level of habituation to the
interventions.
Primary outcome measure
The primary outcome measure will be the foot pain
domain of the Foot Health Status Questionnaire
(FHSQ) [39]. The FHSQ consists of 13 questions that
assess foot health in four domains: ‘foot pain’, ‘foot
function’, ‘footwear’ and ‘general foot health’. There is
a total of four questions under the ‘foot pain’
domain. Questions are scored using a Likert response
format and the participants’ responses are trans-
formed into a score ranging from 0 to 100 for each
domain (0 = worst foot health and 100 = optimal foot
health) [39]. The FHSQ has been subjected to an
extensive validation process, with each domain being
shown to demonstrate high internal consistency
(Cronbach’s α ≥0.851), good reproducibility (intra-
class correlation coefficients (ICCs) ≥0.740) and
discriminant validity [39], as well as good responsive-
ness [40]. Further, the FHSQ is rated as one of the
highest-quality foot health status measures currently avail-
able [41, 42] and has been used previously in clinical trials
of interventions for first MTPJ OA [14, 18, 37].
Secondary outcome measures
The secondary outcome measures will include:
1. Foot-related disability (using the foot function
domain of the FHSQ) [39]
2. Severity of pain at the first MTPJ whilst walking
over a flat surface and during rest over the past
week (each via a 100-mm VAS)
3. Self-reported magnitude of symptom change
(using a 15-point Likert scale where the responses
range from ‘a very great deal better’ to ‘a very
great deal worse’). This variable will then be
dichotomised into the categories of ‘effective’ (‘a
very great deal better’, ‘a great deal better’, ‘a good
deal better’, ‘moderately better’) and ‘ineffective’
(‘somewhat better’, ‘a little better’, ‘about the same,
hardly any better at all’, ‘no change’, ‘about the
same, hardly any worse at all’, ‘a little worse’,
‘somewhat worse’, ‘moderately worse’, ‘a good deal
worse’, ‘a great deal worse’, ‘a very great deal
worse’) [14]
4. Level of physical activity (using the using the
Incidental and Planned Activity Questionnaire
(IPAQ)) [43]
5. Health status (using the Short-Form-12 Version 2
(SF-12®) questionnaire [44] and EuroQol (EQ-5D-
5L™) questionnaire [45])
6. The use of paracetamol rescue medication (number
of participants and mean consumption) and co-
interventions to relieve pain at the first MTPJ,
documented with a monthly diary throughout the
52-week study period [14, 37, 46]
Evaluation of adherence
Adherence to the interventions (shoe inserts and
rehabilitation therapy) in both groups will be assessed at
monthly intervals up to 52 weeks via postal survey. For
the shoe insert interventions, participants will provide
information regarding the number of hours per day and
number of days that they have worn their inserts during
the previous 4 weeks. For the rehabilitation therapy
intervention, participants will provide information
regarding the average number of days per week that they
have performed their exercises during the previous
4 weeks. To minimise participant burden, adherence will
be documented on the day with recall over the previous
4 weeks, rather than by daily diary entries [14, 46, 47].
A summary of the data collection time points for each
of the outcome measures is shown in Fig. 4.
Adverse events
Adverse events from the shoe insert(s) and rehabilitation
therapy (such as skin blistering or the occurrence of new
pain or injuries in other areas of the foot and body) will
be assessed at monthly intervals up to 52 weeks via
postal survey. Participants will be asked to document
the type of adverse event, the body location, the
frequency and/or severity of the event [14, 46, 47]. If
participants experience more significant adverse events
(e.g. severe pain), they will be advised to contact one
investigator who is not involved in recruitment, alloca-
tion or data collection (SEM, KBL, HBM). All adverse
events will be reported in the final manuscript.
Biomechanical evaluation
Biomechanical evaluation will be performed to evaluate
change in biomechanical function of the first MTPJ
using the shoe-stiffening inserts as this is the proposed
mechanism of action of the shoe-stiffening inserts.
Measurement of first MTPJ kinematic variables (range
of motion of first MTPJ and maximum first MTPJ
dorsiflexion) will be performed during level walking, in
addition to kinematic and kinetic analysis of the hip,
knee and ankle. These assessments will be performed at
1 week, rather than baseline, to minimise participant
burden and allow for some level of habituation [36].
Three-dimensional kinematics will be measured using a
10-camera infrared motion analysis system (Vicon
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Fig. 4 SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) diagram of enrolment, interventions and assessments for the
SIMPLE trial
Munteanu et al. Trials  (2017) 18:198 Page 8 of 13
Motion Systems Ltd., Oxford, UK). Two force plates
(Kistler, 9865B, Winterthur, Switzerland and AMTI
OR6, Watertown, MA, USA) will be used to identify gait
cycle events and record kinetic data. Six passive retro-
reflective markers will be attached to the medial forefoot
(three markers) and proximal phalanx of the hallux
(three markers) as required for calculation of first MTPJ
kinematics using the Salford Foot Model [48]. The
Salford Foot Model is a validated five-segment model
that allows calculation of the kinematics of the calcaneus
relative to the tibia, the midfoot relative to the calca-
neus, the lateral forefoot and medial forefoot segments
relative to the midfoot, and the hallux relative to the
medial forefoot. In this study, the kinematics of the
hallux relative to the medial forefoot will be focussed on
in the analysis. This model has been used to assess first
MTPJ kinematics with acceptable reliability [49]. Marker
trajectories (100 Hz) and force plate (4000 Hz) data will
be collected synchronously using Vicon Nexus software
(Vicon Motion Systems Ltd., Oxford, UK). In addition,
32 markers will be fixed to anatomical landmarks of the
trunk, pelvis and lower limb based on the modified
Helen Hayes marker set [50, 51], as well as a customised
model to allow for segmental definition and functional
joint calibration. All lower-limb joint kinematics will be
calculated based on Euler angles and described in terms
of movement of the distal segment relative to the prox-
imal segment. Data will be collected and averaged from
the middle stride of six 10-m walking trials for each
condition. Comparisons between intervention groups
will be made for differences with and without the inter-
vention (shoe-stiffening insert or sham insert) with
participants wearing ‘gait shoes’ (canvas ‘Now’ and
‘IND99’ shoes, Kmart Australia – shoes are the same but
have different branding), which comprise a laced fasten-
ing and canvas upper, and are customised with cut-outs
of the upper in order to allow clear visualisation of the
foot markers (Fig. 5). It is not possible to perform kine-
matic analysis of foot function using participants’ own
closed-in shoes due to the need to attach retro-reflective
markers to the foot landmarks. These analyses will be
adequately powered (power >0.8 assuming n ≥30 and
standard deviation (SD) = 7.5 [8]) to detect a difference
of 5.5° in first MTPJ dorsiflexion range of motion
between the interventions.
Economic evaluation
The economic analysis will take a health service perspec-
tive, assessing the difference in health sector costs and
comparing this with the difference in health outcomes
between treatment and comparison groups. Participants’
time costs will be similar between both groups and do
not affect the comparison. Collection of health service
resource use will be informed by the Australian
Guidelines for Preparing Submissions to the Pharma-
ceutical Benefits Scheme [52]. Participants will be
asked to document their health service use, use of
co-interventions, days unable to work and impair-
ments in physical activity due to first MTPJ OA in
the 4 weeks prior to each survey round (monthly
intervals up to 12 months). Service encounters (e.g.
GP consultations) will be converted to costs using the
Pharmaceutical Benefits Advisory Committee (PBAC)
Manual of Resource Items [53]. Both the cost-
effectiveness and the cost-utility of the intervention
will be determined: the latter as it allows comparisons
of economic value with a broader range of health
service interventions. The cost-effectiveness analysis
will estimate the additional (or incremental) cost per
person achieving a meaningful improvement in the
FHSQ pain score (i.e. larger than the minimal import-
ant difference). The cost-utility analysis will use the
results from the EQ-5D-5L™ to generate a health-
related quality of life utility score at baseline and trial
follow-up, which will be used to estimate change
across the two groups. From this, an incremental cost
per quality-adjusted life year will be derived.
Fig. 5 Marker placement for measurement of first metatarsophalangeal
joint (MTPJ) kinematics. The effect of the inserts on first MTPJ kinematics
will be performed using the Salford Foot Model with participants
wearing ‘gait shoes’ that have been customised with cut-outs of
the upper in order to allow clear visualisation of the foot markers.
Upper panel: medial view; Lower panel: lateral view
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Probabilistic sensitivity analyses will be conducted,
incorporating confidence limits on the plausible range
of costs and effects used in the analysis.
Sample size
The sample size has been determined a priori using
SPSS Sample Power 3.0 (IBM Corp., Armonk, NY, USA)
based on the FHSQ pain domain as the primary
outcome measure. Using a power of 90%, minimal im-
portant difference of 12.5 points in the foot pain domain
of the FHSQ [37, 54], SD of 16.8 (based on the 12-week
time point in our recent trial [14]), assuming a 10%
dropout rate, and a significance level set at α < 0.05, we
estimated that a total of 90 participants will be required.
Statistical analysis
Statistical analysis will be performed using the most re-
cent version of SPSS (IBM Corp., Armonk, NY, USA)
available at the time of analysis. Analysis will adhere to
the intention-to-treat principle for all randomised partic-
ipants. In participants with bilateral symptoms, the more
painful foot will be analysed (or the right foot if they
cannot define the more painful foot) to maintain inde-
pendence of data. Multiple imputation will be used to
replace any missing data using five iterations, with sex,
age, baseline scores and group allocation as predictors.
The exception will be for the following variables where
no data substitution will be applied: self-reported magni-
tude of symptom change, use of co-interventions, and
adverse events. Standard tests to assess continuous data
for normal distribution will be used and transformation
carried out if required. The primary outcome measure
will be the foot pain domain of the FHSQ measured at
12 weeks. To avoid over-testing and to minimise the risk
of type I error associated with serial measurements, stat-
istical analysis of the effectiveness of the interventions
will specifically focus on the change in primary outcome
measures between baseline and 12 weeks [55, 56], and
differences in the primary and secondary outcome mea-
sures between the two groups will be compared at
12 weeks. Continuously scored outcome measures
(FHSQ foot pain domain, FHSQ foot function domain,
severity of pain at the first MTPJ whilst walking over a
flat surface and during rest in the previous week, level of
physical activity using the IPAQ, and health status using
the SF-12® and EQ-5D-5L™) will be analysed using
analysis of covariance with the intervention group and
baseline scores entered as independent variables. Self-
reported magnitude of symptom change will be com-
pared using relative risk, risk difference and number
needed to treat (NNT). Use of paracetamol rescue medi-
cation and intervention adherence will be compared
using independent groups t tests. Use of co-interventions
and frequency of adverse events will be compared using
relative risk and risk difference statistics. For the biomech-
anical evaluation, first MTPJ range of motion and
maximum first MTPJ dorsiflexion will be compared
between groups using analysis of covariance with the
intervention group and shoe-only condition scores
entered as independent variables.
Discussion
Osteoarthritis of the first MTPJ is highly prevalent and
causes significant pain and disability in those affected.
Developing effective interventions for first MTPJ OA is,
therefore, a high priority. At present, there is little
evidence to guide management of this condition as, to
our knowledge, there are only three clinical trials that
have been published [13, 14, 37]. Consequently, the
choice of intervention is currently a matter of trial and
error, leading to increased costs and prolonged disability.
We will address this issue by conducting a rigorous
randomised controlled trial and economic analysis to
evaluate the effectiveness of shoe-stiffening inserts for
reducing foot pain, improving mobility and health-
related quality of life in people with first MTPJ OA.
In this trial, both intervention groups will receive a
standardised programme of rehabilitation therapy that is
based on a physiotherapy programme for first MTPJ OA
which has been reported to be effective in a randomised
trial [13]. The therapy will be performed daily for the
initial 12 weeks then three times per week for the
remainder of the trial (up to 52 weeks). The programme
to be used in this trial is similar to the previous trial [13]
in that it involves mobilisation of the first MTPJ and
strengthening of the plantar-flexor muscles of the first
MTPJ. However, it does differ from the previous trial
[13] in a number of ways: (1) it is primarily a home-
based programme rather than a clinician-administered
programme, (2) the duration will be 52 weeks rather
than 4 weeks, (3) it will be performed daily during the
initial 12 weeks, rather than three times per week, (4) a
heat pack will be used to increase soft tissue extensibility
at the start of each session rather than a hot whirlpool
bath and therapeutic ultrasound, (5) mobilisation of the
first MTPJ will involve the first metatarsal and proximal
phalanx (and will not include sesamoid mobilisation), (6)
gastrocnemius and hamstring muscle stretching will not
be performed, (7) active plantarflexion of the ankle joint
and a marble pick-up exercise with the toes will not be
performed, (8) ‘gait training’ will not be prescribed and
(9) a cold pack rather than electrical stimulation will be
used at the conclusion of each session. We have
amended the programme because (1) we believe that
elements of the programme in the previous trial [13] are
unlikely to be of clinical benefit in first MTPJ OA, (2)
the programme will need to be performed for 52 weeks
rather than 4 weeks, so minimising participant burden is
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important and (3) it will primarily be a home-based
programme, so needs to be simple to perform. Import-
antly, a rehabilitation therapy programme has been
included as a co-treatment as an ethical requirement,
since using a sham treatment alone could be considered
withholding ‘usual’ care.
Poor adherence by participants to their shoe insert
intervention and/or rehabilitation therapy programme has
the potential to confound the study results. In our previ-
ous case series study, adherence to the shoe-stiffening
inserts was excellent, with the shoe-stiffening inserts being
reported to be worn for a mean of 42 h per week at
3 months [18]. Furthermore, in a previous trial investigat-
ing the effectiveness of a 4-week clinician-administered
rehabilitation therapy programme for first MTPJ OA by
Shamus et al. [13], adherence was reported to be 100%.
Therefore, we anticipate that adherence to our interven-
tions will be satisfactory in the short to intermediate term
in our trial (12 weeks). Participant adherence may reduce
over the course of this trial given its extended duration
(52 weeks). However, to maximise adherence, participants
will be (1) telephoned at monthly intervals to remind
them to perform the rehabilitation programme and (2)
asked to complete diary entries regarding the use of their
shoe inserts and completion of the rehabilitation
programme that will be returned at monthly intervals.
This trial will incorporate five repeated measurements
for the primary outcome measure (baseline, 4, 12, 24
and 52 weeks) to provide insights into the trajectory of
any improvements in symptoms. The three previous
clinical trials investigating nonsurgical interventions for
first MTPJ OA have used study durations of 4 [13], 12
[14] and 24 [37] weeks. Incorporating a 52-week follow-
up period is a major strength of our study as it will enable
us to determine the short- (4 weeks), intermediate-
(12 weeks) and longer-term (24 and 52 weeks) effects of
the shoe-stiffening inserts, if any. A 52-week follow-up is
also important to allow the capture of important costs and
effects for the planned economic analysis [57].
This will be the first trial to perform an economic
analysis of any nonsurgical intervention for first MTPJ
OA. Inclusion of such an analysis is important because the
acceptance and use of novel interventions is determined by
their cost as well as by their clinical effectiveness [58].
Results from this study will, therefore, be of value to both
clinicians and health care policy-makers. Recruitment of
participants will commence in April 2016 and final results
are expected to be available in December 2018.
Trial status
Advertising for participants commenced in April 2016
with the first participant being enrolled on 16 June
2016. The final results are expected to be available in
December 2018.
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